Meeting
2022 ASCO Annual Meeting
Phase 3 randomised study evaluating the addition of low-dose nivolumab to palliative chemotherapy in head and neck cancer.
Authors
Vijay Maruti Patil
Tata Memorial Centre, Mumbai, India
Vijay Maruti Patil , Vanita Noronha , Nandini Sharrel Menon , Atanu Bhattacharjee , Suman Kumar , Nilendu Purandare , Archi Agrawal , Ameya Puranik , Kavita Prakash Nawale , Shweta Jogdhankar , Mitali Alone , Rupali Tambe , Riddhi Sawant , Devanshi Kalra , Sachin Babanrao Dhumal , Shripad Dinanath Banavali , Kumar Prabhash
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
CTRI/2020/11/028953
Citation
J Clin Oncol 40, 2022 (suppl 17; abstr LBA6016)
DOI
10.1200/JCO.2022.40.17_suppl.LBA6016
Abstract #
LBA6016
Poster Bd #
8
Abstract Disclosures
Similar Posters
First Author: Martin H. Schuler
First Author: Akhil Kapoor
Poster
2023 ASCO Annual Meeting
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
First Author: Patrick M. Forde
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
First Author: Oxana V. Crysler